Interaction of St John's wort with low‐dose oral contraceptive therapy: a randomized controlled trial
- 23 October 2003
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 56 (6) , 683-690
- https://doi.org/10.1046/j.1365-2125.2003.02005.x
Abstract
Breakthrough bleeding or even unwanted pregnancies have been reported in women during concomitant therapy with oral contraceptives and St John's wort extract. The aim of the present study was to investigate the effects of St John's wort extract on oral contraceptive therapy with respect to ovarian activity, breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel. Eighteen healthy females were treated with a low-dose oral contraceptive (0.02 mg ethinyloestradiol, 0.150 mg desogestrel) alone (control cycle) or combined with 300 mg St John's wort extract given twice daily (cycle A) or three times daily (cycle B). Ovarian activity was assessed by measuring follicle maturation and serum oestradiol and progesterone concentrations. The number of breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel were assessed under steady-state conditions. During concomitant administration of low-dose oral contraceptive and St John's wort, there was no significant change in follicle maturation, serum oestradiol or progesterone concentrations when compared with oral contraceptive treatment alone. However, significantly more subjects reported intracyclic bleeding during cycles A (13/17 (77%), P < 0.015) and cycle B (15/17 (88%), P < 0.001) than with oral contraceptives alone (6/17 (35%)). The AUC(0,24 h) and Cmax of ethinyloestradiol remained unchanged during all study cycles, whereas the AUC(0,24 h) and Cmax of 3-ketodesogestrel decreased significantly from 31.2 ng ml−1 h to 17.7 ng ml−1 h (43.9%; 95% confidence interval (CI) −49.3, −38.5, P = 0.001) and from 3.6 ng ml −1 to 3.0 ng ml −1(17.8%; CI −29.9, −5.7, P = 0.005), respectively, during cycle A and by 41.7% (CI −47.9, −35.6; P = 0.001) and by 22.8% (CI −31.2, −13.3; P < 0.001) during cycle B respectively, compared with the control cycle. There was no evidence of ovulation during low-dose oral contraceptive and St John's wort extract combination therapy, but intracyclic bleeding episodes increased. Bleeding irregularities may adversely effect compliance to oral contraceptives and together with St John's wort-induced decreases in serum 3-ketodesogestrel concentrations, enhance the risk of unintended pregnancies.Keywords
This publication has 33 references indexed in Scilit:
- Unwanted pregnancy on self‐medication with St John's wort despite hormonal contraceptionBritish Journal of Clinical Pharmacology, 2003
- St John's wort (Hypericum perforatum): drug interactions and clinical outcomesBritish Journal of Clinical Pharmacology, 2002
- St John's Wort increases expression of P‐glycoprotein: Implications for drug interactionsBritish Journal of Clinical Pharmacology, 2002
- Saint John's wort: An in vitro analysis of P‐glycoprotein induction due to extended exposureBritish Journal of Pharmacology, 2001
- Equivalence of St Johnʼs wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mildmoderate depressionInternational Clinical Psychopharmacology, 2000
- Effects of cytochrome P450 inducers on 17α-ethinyloestradiol (EE2 ) conjugation by primary human hepatocytesPublished by Wiley ,1999
- The effect of desogestrel, gestodene, and other factors on spotting and bleedingContraception, 1996
- Reliability and Validity of the Short Portable Mental Status Questionnaire Administered by TelephoneJournal of Geriatric Psychiatry and Neurology, 1994
- Good Clinical Practice for Trials on Medicinal Products in the European Community: CPMP Working Party on Efficacy of Medicinal ProductsBasic & Clinical Pharmacology & Toxicology, 1990
- Metabolism of 17 α-ethynylestradiol in humansLife Sciences, 1990